CN100522166C - 用作组胺h3拮抗剂的(1-4-哌啶基)苯并咪唑衍生物 - Google Patents

用作组胺h3拮抗剂的(1-4-哌啶基)苯并咪唑衍生物 Download PDF

Info

Publication number
CN100522166C
CN100522166C CNB038137798A CN03813779A CN100522166C CN 100522166 C CN100522166 C CN 100522166C CN B038137798 A CNB038137798 A CN B038137798A CN 03813779 A CN03813779 A CN 03813779A CN 100522166 C CN100522166 C CN 100522166C
Authority
CN
China
Prior art keywords
alkyl
aryl
compound
alkoxy
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038137798A
Other languages
English (en)
Chinese (zh)
Other versions
CN1658874A (zh
Inventor
Q·曾
R·G·阿斯拉尼安
M·Y·伯林
C·W·博伊斯
J·曹
J·A·科兹罗夫斯基
P·曼加拉茨纳
K·D·麦科尔米克
M·W·穆塔希
S·B·罗森布卢姆
N·-Y·施
D·M·索洛蒙
W·C·托姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1658874A publication Critical patent/CN1658874A/zh
Application granted granted Critical
Publication of CN100522166C publication Critical patent/CN100522166C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038137798A 2002-04-18 2003-04-16 用作组胺h3拮抗剂的(1-4-哌啶基)苯并咪唑衍生物 Expired - Fee Related CN100522166C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37373102P 2002-04-18 2002-04-18
US60/373,731 2002-04-18

Publications (2)

Publication Number Publication Date
CN1658874A CN1658874A (zh) 2005-08-24
CN100522166C true CN100522166C (zh) 2009-08-05

Family

ID=29251069

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038137798A Expired - Fee Related CN100522166C (zh) 2002-04-18 2003-04-16 用作组胺h3拮抗剂的(1-4-哌啶基)苯并咪唑衍生物

Country Status (26)

Country Link
EP (1) EP1499316B1 (https=)
JP (1) JP4384918B2 (https=)
KR (1) KR100827470B1 (https=)
CN (1) CN100522166C (https=)
AR (1) AR040405A1 (https=)
AT (1) ATE389406T1 (https=)
AU (1) AU2003223627B2 (https=)
BR (1) BR0309348A (https=)
CA (1) CA2481940A1 (https=)
CY (1) CY1110363T1 (https=)
DE (1) DE60319813T2 (https=)
DK (1) DK1499316T3 (https=)
EC (1) ECSP045367A (https=)
ES (1) ES2301791T3 (https=)
IL (1) IL164584A (https=)
MX (1) MXPA04010173A (https=)
NO (1) NO20045002L (https=)
NZ (1) NZ535763A (https=)
PE (1) PE20040684A1 (https=)
PL (1) PL373889A1 (https=)
PT (1) PT1499316E (https=)
RU (1) RU2323935C2 (https=)
SI (1) SI1499316T1 (https=)
TW (1) TW200306183A (https=)
WO (1) WO2003088967A1 (https=)
ZA (1) ZA200407984B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE552236T1 (de) 2003-01-14 2012-04-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz
CA2523431A1 (en) 2003-04-23 2004-11-25 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
ES2522579T3 (es) 2004-06-17 2014-11-17 Cytokinetics, Inc. Compuestos, composiciones y métodos
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
US20080021069A1 (en) * 2004-10-08 2008-01-24 Takeda Pharmaceutical Company Limited Receptor Function Regulating Agent
EP1848696A1 (en) * 2005-01-21 2007-10-31 Schering Corporation Imidazole and benzimidazole derivates useful as histamine h3 antagonists
TW200738676A (en) * 2005-06-20 2007-10-16 Schering Corp Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
ATE450525T1 (de) * 2005-06-20 2009-12-15 Schering Corp Kohlenstoffgebundene substituierte piperidine und derivate daraus als histamin-h3-antagonisten
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
WO2007035703A1 (en) * 2005-09-20 2007-03-29 Schering Corporation 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist
ATE429428T1 (de) 2005-09-30 2009-05-15 Hoffmann La Roche Indanderivate als antagonisten des mch-rezeptors
ES2419007T3 (es) 2005-12-15 2013-08-19 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y procedimientos
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007078839A2 (en) 2005-12-19 2007-07-12 Cytokinetics, Inc. Compounds, compositions and methods
US7638531B2 (en) 2005-12-21 2009-12-29 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
EP1965862A2 (en) * 2005-12-21 2008-09-10 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
RU2008132966A (ru) * 2006-01-13 2010-02-20 Ф.Хоффманн-Ля Рош Аг (Ch) Производные циклогексилпиперазинилметанона и их применение в качестве модуляторов гистамин н3 рецептора
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
CN101809021B (zh) * 2007-09-11 2013-04-24 雅培制药有限公司 八氢-吡咯并[3,4-b]吡咯n-氧化物
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
CA2785536C (en) 2009-12-30 2018-02-27 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
WO2012177852A1 (en) 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
US8609688B2 (en) 2011-06-24 2013-12-17 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
KR101127756B1 (ko) 2011-09-02 2012-03-23 한국과학기술원 Ｇｉｔ１ 유전자 결손 마우스 및 이를 이용한 약물 스크리닝 방법
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
JP6046646B2 (ja) * 2014-01-10 2016-12-21 信越化学工業株式会社 オニウム塩、化学増幅型ポジ型レジスト組成物、及びパターン形成方法
US10595550B2 (en) * 2014-01-22 2020-03-24 Vision Pharma, Llc Therapeutic composition including carbonated solution
WO2017035114A1 (en) * 2015-08-25 2017-03-02 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as cb-1 inverse agonists
MA55556A (fr) 2019-04-02 2022-02-09 Aligos Therapeutics Inc Composés ciblant prmt5

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580541A1 (en) * 1992-07-20 1994-01-26 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) New piperidine derivatives of benzimidazole as antihistanminic and antiallergic agents
CN1211246A (zh) * 1996-02-21 1999-03-17 赫彻斯特马里恩鲁斯公司 用于治疗过敏性疾病的新的取代的n－甲基－n－(4－(4－(1h－苯并咪唑－2－基氨基)哌啶－1－基)－2－ (芳基)丁基)苯甲酰胺
CN1323302A (zh) * 1998-10-16 2001-11-21 先灵公司 作为组胺－h3激动剂或拮抗剂的n－(咪唑基烷基)取代的环胺
WO2002032893A2 (en) * 2000-10-17 2002-04-25 Schering Corporation Piperidine compounds as anti-allergic

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD290192A5 (de) * 1986-11-13 1991-05-23 Eisai Co. Ltd,Jp Pyridinderivat mit antiulzeroeser wirkung
DE69415391T2 (de) * 1993-05-26 1999-08-26 Sumitomo Pharmaceuticals Co. Chinazolinonderivate
US6211199B1 (en) * 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
EP0980359B1 (en) * 1997-05-01 2004-06-23 Nissan Chemical Industries, Ltd. Benzimidazole derivative
AU2001292730A1 (en) * 2000-09-20 2002-04-02 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists
US7220735B2 (en) * 2002-04-18 2007-05-22 Schering Corporation Benzimidazolone histamine H3 antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580541A1 (en) * 1992-07-20 1994-01-26 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) New piperidine derivatives of benzimidazole as antihistanminic and antiallergic agents
CN1211246A (zh) * 1996-02-21 1999-03-17 赫彻斯特马里恩鲁斯公司 用于治疗过敏性疾病的新的取代的n－甲基－n－(4－(4－(1h－苯并咪唑－2－基氨基)哌啶－1－基)－2－ (芳基)丁基)苯甲酰胺
CN1323302A (zh) * 1998-10-16 2001-11-21 先灵公司 作为组胺－h3激动剂或拮抗剂的n－(咪唑基烷基)取代的环胺
WO2002032893A2 (en) * 2000-10-17 2002-04-25 Schering Corporation Piperidine compounds as anti-allergic

Also Published As

Publication number Publication date
NO20045002L (no) 2005-01-18
PE20040684A1 (es) 2004-10-05
AU2003223627B2 (en) 2006-10-12
RU2323935C2 (ru) 2008-05-10
MXPA04010173A (es) 2005-02-03
SI1499316T1 (sl) 2008-08-31
PL373889A1 (en) 2005-09-19
ZA200407984B (en) 2005-10-18
PT1499316E (pt) 2008-06-30
BR0309348A (pt) 2005-03-01
JP4384918B2 (ja) 2009-12-16
CY1110363T1 (el) 2012-05-23
AU2003223627C1 (en) 2003-11-03
IL164584A (en) 2010-12-30
EP1499316B1 (en) 2008-03-19
JP2005529116A (ja) 2005-09-29
DE60319813T2 (de) 2009-04-23
DK1499316T3 (da) 2008-07-21
DE60319813D1 (de) 2008-04-30
TW200306183A (en) 2003-11-16
ECSP045367A (es) 2004-11-26
EP1499316A1 (en) 2005-01-26
AR040405A1 (es) 2005-04-06
ES2301791T3 (es) 2008-07-01
KR20040099445A (ko) 2004-11-26
KR100827470B1 (ko) 2008-05-06
IL164584A0 (en) 2005-12-18
NZ535763A (en) 2007-06-29
RU2004133764A (ru) 2005-07-20
ATE389406T1 (de) 2008-04-15
AU2003223627A1 (en) 2003-11-03
HK1067981A1 (en) 2005-04-22
CA2481940A1 (en) 2003-10-30
WO2003088967A1 (en) 2003-10-30
CN1658874A (zh) 2005-08-24

Similar Documents

Publication Publication Date Title
CN100522166C (zh) 用作组胺h3拮抗剂的(1-4-哌啶基)苯并咪唑衍生物
CN100497334C (zh) 用作组胺h3拮抗剂的吲哚衍生物
CN100360130C (zh) 用作组胺h3拮抗剂的1－(4－哌啶基)苯并咪唑酮
US7105505B2 (en) Benzimidazole derivatives useful as histamine H3 antagonists
JP4025200B2 (ja) ピペリジンｍｃｈアンタゴニストおよび肥満の処置におけるそれらの使用
CN109415359B (zh) 杂环gpr119激动剂化合物
JP2000514821A (ja) ピラゾロピリジン化合物およびその医薬用途
HK1067981B (en) (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists
HK1101691A (en) Indole derivatives useful as histamine h3 antagonists
JPH1180157A (ja) ピラゾロピリジンアデノシン拮抗剤
HK1072259B (en) Indole derivatives useful as histamine h3 antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090805

Termination date: 20110416